Cerba Research offers state-of-the-art genomic technologies to obtain the essential dataset from your liquid tumors, such as multiple myeloma, acute myeloid leukemia, myeloproliferative neoplasms, and more

Next Generation Sequencing Capabilities for Liquid Tumours

Cerba Research is proud to offer a full range of next-generation sequencing capabilities for your liquid tumors clinical trial specimens.

We have broad panel assays to cover indications such as myeloproliferative syndrome, acute myeloid leukemia, myeloid tumors, lymphoproliferative syndromes and more.

Discover how we can help you to unlock the genomics information from your liquid tumor specimens.

Cerba Paris Comprehensive Hematological Malignancies Panels

Panel Name Genes Tumor Type Instrument TAT Bone marrow Peripheral blood FFPE
MPN Panel 15 Myeloproliferative neoplasms NextSeq 15 X X
MDS/CMML Panel 32 Myelodysplastic syndromes, CMML NextSeq 15 X X
AML Panel 36 Acute myeloid leukemia NextSeq 15 X X
Pan-myeloid Panel AML / MDS / CMML / MPN 40 Myeloid tumors, CMML, MDS NextSeq 15 X X
Mature Lymphoid Panel 10 Lymphoproliferative syndromes NextSeq 15 X X

Cerba Research Liquid Tumor NGS Landscape

Benefit from our capabilities and expertise to obtain the dataset you need for your liquid tumor clinical trial

Next Generation Sequencing

A full range of gene panels available

Myelo proliferative neoplasms
Chronic Myelomonosystic leukemia and myelodysplasic syndroms
Acute Myeloblastic leukemia
Lymphoid malignancies

qPCR

BCR-ABL
AML1-ETO / RUNX1 – RUNX1T1
PML-RARA
CBFB – MYH11

Digital PCR

JAK2 V617F
MYD88

Caryotype/FISH

All hematological malignancies

Fragment Analysis

B/T Clonality
AML/MPNs Analysis

Reach out to our genomics team and see how we can help advance your research with our Hematological Malignancies NGS capabilities